Dec 20 (Reuters) - Kalytera Therapeutics Inc KALY.V :
* KALYTERA PROVIDES UPDATE ON PHASE 2 CLINICAL STUDY EVALUATING CBD IN PREVENTION OF ACUTE GVHD
* KALYTERA THERAPEUTICS - POSITIVE INTERIM DATA FROM ONGOING PHASE 2 CLINICAL STUDY EVALUATING CANNABIDIOL
* KALYTERA THERAPEUTICS - NO PATIENTS RECEIVING ORAL CBD AT LOWEST STUDY DOSE OF 75 MG TWICE DAILY HAVE DEVELOPED GRADES 3 OR 4 ACUTE GVHD
* KALYTERA THERAPEUTICS INC - CBD HAS DEMONSTRATED A GOOD SAFETY AND TOLERABILITY PROFILE, WITH NO SIGNIFICANT ADVERSE EVENTS RELATING TO ITS USE.
* KALYTERA THERAPEUTICS INC - ONE PATIENT DEVELOPED GRADE 2 ACUTE GVHD, LEAST SERIOUS FORM OF DISEASE.
* KALYTERA THERAPEUTICS INC - EXPECT TO INITIATE PHASE 3 STUDY IN 2019
* KALYTERA THERAPEUTICS - ANTICIPATED THAT ALL OF PATIENTS IN FIRST COHORT WILL HAVE COMPLETED ENTIRE 105-DAY COURSE OF TREATMENT WITH CBD BY FEB 28, 2019